ICLUSIG (ponatinib) delivered clinically meaningful response in Ph+ ALL1,2
IN THE PACE TRIAL
The PACE trial showed ICLUSIG monotherapy helped difficult-to-treat patients
with Ph+ ALL achieve a response1,2
In PACE, the starting dose of ICLUSIG (ponatinib) was 45 mg administered orally once daily, given as a single agent. Median duration of follow-up for the Ph+ ALL cohort was 6 months.2 Patients with uncontrolled hypertriglyceridemia and patients with clinically significant or active cardiovascular disease, including any history of clinically significant atrial/ventricular arrhythmias or history of myocardial infarction, unstable angina, or congestive heart failure within the 3 months prior to the first dose of ICLUSIG (ponatinib), were excluded.1,2
Patient characteristics
Patient characteristics
69% of patients with Ph+ ALL were T315I+ in the PACE trial3
Patients taking ICLUSIG reached important markers of response1
41% of patients achieved MaHR by 6 months1,a,b (n=32)
The primary efficacy endpoint for Ph+ ALL was MaHR by 6 months1
- Median time to MaHR 0.7 months (range: 0.4-6.0 months)1
- Median duration of MaHR 3.5 months (range: 1.9-13.7 months)1
- Median duration of follow-up for the Ph+ ALL cohort was 6 months.4
aThe primary endpoint for Ph+ ALL of MaHR by 6 months combined complete hematologic responses (CHR) and no evidence of leukemia.1
bCHR: WBC ≤ institutional ULN; ANC ≥1000/mm3; platelets ≥100,000/mm3; no blasts or promyelocytes in peripheral blood; bone marrow blasts ≤5; <5% myelocytes plus metamyelocytes in peripheral blood; basophils <5% in peripheral blood; and no extramedullary involvement (including no hepatomegaly or splenomegaly).1